GlassScriptPhysician profile
Eric I Vogt
NPI 1164534640
$2,452.58
in general payments reported to CMS, 2019-2025
27 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $324 · 2021: $616 · 2022: $393 · 2023: $292 · 2024: $134 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $788.13 | 2019-2023 | Xtandi, Myrbetriq |
| Abbvie INC. | $324.54 | 2019-2025 | Botox |
| Myriad Genetic Laboratories, INC. | $288.95 | 2021-2025 | Prolaris |
| Boston Scientific Corporation | $135.02 | 2019-2020 | |
| Medtronic, INC. | $108.72 | 2021-2025 | Interstim, Altaviva |
| Teleflex LLC | $99.61 | 2022 | |
| Myovant Sciences INC. | $93.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.92 | 2021-2023 | |
| Janssen Biotech, INC. | $73.20 | 2022-2023 | Erleada |
| Coloplast Corp | $55.77 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $47.14 | 2020 | |
| Sumitomo Pharma America, INC. | $43.93 | 2024 | Gemtesa |
| Axonics, INC. | $34.90 | 2020-2021 | |
| Pfizer INC. | $33.79 | 2019-2020 | |
| Medtronic USA, INC. | $33.56 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.11 | 2019 | |
| 180 Medical, INC. | $25.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.91 | 2024 | Vonvendi |
| Tolmar Pharmaceuticals, INC. | $17.41 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $16.80 | 2019 | |
| Merck Sharp & Dohme LLC | $15.36 | 2022 | |
| Dentsply Ih INC. | $14.32 | 2019 | |
| Urovant Sciences INC | $12.37 | 2022 | |
| Travere Therapeutics, INC. | $12.17 | 2021 | |
| Ambu INC. | $11.85 | 2022 | |
| Zyla Life Sciences, INC. | $11.65 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.